Jyothi Datta

Public health experts are calling for greater transparency involving specifics on why the eyedrops were recalled, besides seeking regulatory intervention and advisory for those who may have already used the drops

With six antibiotic products in different stages of research and launch in its basket, drugmaker Wockhardt has set up an antibiotic academy to dialogue with practitioners to share real-world clinical data and promote the rational use of antibiotics, said Founder Chairman Habil Khorakiwala.

Future Health Index 2026 report finds physicians getting more time to see patients

In their letter to the Union Health Minister JP Nadda, they said, medical devices continue to be seen as “an adjunct to pharmaceuticals” , despite scientific, engineering and regulatory distinctions between the two.

Unhappy with being equated to the hospitality industry, healthcare associations are pointing to their layered costs and several compliances that add to their costs.

India cannot work in silos, aligning with internationally recognised systems would ensure that the product, batch, and expiry information were encoded in a universal manner: Swaminathan

The cost of healthcare has been at the heart of several discussions recently, following a recent Parliamentary panel report that red-flagged medical bills at private hospitals

Udaya Bhaskar, with the All India Drugs Control Officers’ Confederation, points out that ophthalmologists had flagged concerns involving certain eye drops in June

Explore how foreign investment and corporatisation are reshaping India's healthcare landscape and affecting patient care and costs.

PH Kurian, a pivotal public servant, championed public health by issuing India's first compulsory license for affordable cancer treatment.